Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hepatitis C × Sorafenib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 62 Carcinoma, Renal Cell 35 Liver Neoplasms 17 Carcinoma, Non-Small-Cell Lung 15 Breast Neoplasms 14 Neoplasms 13 Neoplasm Metastasis 13 Melanoma 12 Leukemia, Myeloid, Acute 10 Sarcoma 9 Thyroid Neoplasms 8 Lung Neoplasms 8 Kidney Neoplasms 8 Prostatic Neoplasms 7 Pancreatic Neoplasms 6 Urinary Bladder Neoplasms 5 Ovarian Neoplasms 5 Colorectal Neoplasms 5 Glioblastoma 4 Carcinoma, Medullary 4 Breast Neoplasms, Male 4 Brain Neoplasms 4 Thyroid Diseases 3 Thyroid Carcinoma, Anaplastic 3 Stomach Neoplasms 3 Recurrence 3 Osteosarcoma 3 Myelodysplastic Syndromes 3 Leiomyosarcoma 3 Hemangiosarcoma 3

Interventions

ledipasvir, sofosbuvir drug combination 2 Ribavirin 2 pembrolizumab 1 grazoprevir 1 elbasvir-grazoprevir drug combination 1 elbasvir 1 Sorafenib 1 Sofosbuvir 1 Medical Marijuana 1 Immunoenzyme Techniques 1 Chromatography, High Pressure Liquid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04710641 2025-03-06

OUTREACH2

Mina Alpha Limited

Phase 2 Completed

Gastrointestinal

Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡